Risk of Hypersensitivity Reactions to Iopromide After Intra-Arterial Versus Intravenous Administration
| Autor: | Jan Endrikat, Kai Vogtländer, Alexander Michel, Philipp Lengsfeld, Ralf Kölbach |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Allergy iopromide Erythema Iohexol Contrast Media hypersensitivity reactions Gastroenterology 030218 nuclear medicine & medical imaging Drug Hypersensitivity intra-arterial administration Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Radiology Nuclear Medicine and imaging business.industry Iopromide Case-control study Original Articles General Medicine Odds ratio Middle Aged medicine.disease Rash Hypersensitivity reaction Injections Intra-Arterial Case-Control Studies Nested case-control study Administration Intravenous Female medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Investigative Radiology |
| ISSN: | 0020-9996 |
| DOI: | 10.1097/rli.0000000000000611 |
| Popis: | Objective The aim of this study was to compare the risk of hypersensitivity reactions to iopromide after intra-arterial (IA) administration and intravenous (IV) administration. Materials and Methods Four observational studies were pooled. Almost half of the study population (48.1%) was from Europe, and one quarter each from China (27.6%) and other Asia countries (24.1%). All patients received iopromide either intra-arterially or intravenously for angiographic procedures (mostly cardio-angiography) or contrast-enhanced computed tomography. A nested case-control analysis, including a multivariable logistic regression model, was performed. Cases were defined by patients with a typical and unequivocal hypersensitivity (assumed non–IgE-mediated) reaction; controls were patients without any recorded reaction. The primary target variable is the odds ratio of having a hypersensitivity reaction after IA versus IV administration. Results A total of 133,331 patients met the inclusion criteria, 105,460 and 27,871 patients received iopromide IV or IA, respectively. Hypersensitivity reactions were recorded for 822 patients, and 132,509 patients served as controls. Major risk factors for hypersensitivity reactions were method of injection (IV vs IA), age (18 to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|